Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Impact · against what's priced in

Positive Phase 3 data for zoliflodacin increases the probability of regulatory approval and future revenue streams for Innoviva. This publication in The Lancet provides clinical validation for a pivotal trial, moving the asset closer to commercialization.

INVA+0.60

No priced-in read yet